Satellos wins FDA IND clearance for forazapadin in FSHD
Satellos won FDA clearance for its IND to test forazapadin in facioscapulohumeral muscular dystrophy. FSHD Canada Foundation committed up to USD 5 million in non-dilutive milestone funding for the program. Phase 2 proof-of-concept trial planned for Q4 2026. Disclaimer: This news brief was created by Public Technologies